Literature DB >> 10819950

Association of coffee and caffeine intake with the risk of Parkinson disease.

G W Ross1, R D Abbott, H Petrovitch, D M Morens, A Grandinetti, K H Tung, C M Tanner, K H Masaki, P L Blanchette, J D Curb, J S Popper, L R White.   

Abstract

CONTEXT: The projected expansion in the next several decades of the elderly population at highest risk for Parkinson disease (PD) makes identification of factors that promote or prevent the disease an important goal.
OBJECTIVE: To explore the association of coffee and dietary caffeine intake with risk of PD. DESIGN, SETTING, AND PARTICIPANTS: Data were analyzed from 30 years of follow-up of 8004 Japanese-American men (aged 45-68 years) enrolled in the prospective longitudinal Honolulu Heart Program between 1965 and 1968. MAIN OUTCOME MEASURE: Incident PD, by amount of coffee intake (measured at study enrollment and 6-year follow-up) and by total dietary caffeine intake (measured at enrollment).
RESULTS: During follow-up, 102 men were identified as having PD. Age-adjusted incidence of PD declined consistently with increased amounts of coffee intake, from 10.4 per 10,000 person-years in men who drank no coffee to 1.9 per 10,000 person-years in men who drank at least 28 oz/d (P<.001 for trend). Similar relationships were observed with total caffeine intake (P<.001 for trend) and caffeine from non-coffee sources (P=.03 for trend). Consumption of increasing amounts of coffee was also associated with lower risk of PD in men who were never, past, and current smokers at baseline (P=.049, P=.22, and P=.02, respectively, for trend). Other nutrients in coffee, including niacin, were unrelated to PD incidence. The relationship between caffeine and PD was unaltered by intake of milk and sugar.
CONCLUSIONS: Our findings indicate that higher coffee and caffeine intake is associated with a significantly lower incidence of PD. This effect appears to be independent of smoking. The data suggest that the mechanism is related to caffeine intake and not to other nutrients contained in coffee. JAMA. 2000;283:2674-2679.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10819950     DOI: 10.1001/jama.283.20.2674

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  176 in total

Review 1.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

2.  Cohort studies in health sciences librarianship.

Authors:  Jonathan Eldredge
Journal:  J Med Libr Assoc       Date:  2002-10

3.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

Review 4.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

5.  Parkinson's disease research in a prospective cohort in China.

Authors:  Honglei Chen; Ding Ding; Jian Wang; Qianhua Zhao; Haijiao Meng; Honglan Li; Yu-Tang Gao; Xiao-Ou Shu; Caroline M Tanner; Zhen Hong; Gong Yang
Journal:  Parkinsonism Relat Disord       Date:  2015-08-20       Impact factor: 4.891

Review 6.  Beneficial and detrimental role of adenosine signaling in diseases and therapy.

Authors:  Hong Liu; Yang Xia
Journal:  J Appl Physiol (1985)       Date:  2015-08-27

7.  Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.

Authors:  Iris Y Kim; Éilis J O'Reilly; Katherine C Hughes; Xiang Gao; Michael A Schwarzschild; Marjorie L McCullough; Marian T Hannan; Rebecca A Betensky; Alberto Ascherio
Journal:  Mov Disord       Date:  2018-01-10       Impact factor: 10.338

Review 8.  Caffeine in tea Camellia sinensis--content, absorption, benefits and risks of consumption.

Authors:  A Gramza-Michałowska
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

9.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Honglei Chen; Thomas H Mosley; Alvaro Alonso; Xuemei Huang
Journal:  Am J Epidemiol       Date:  2009-03-18       Impact factor: 4.897

Review 10.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.